Anecortave
From Wikipedia, the free encyclopedia
Anecortave
|
|
Systematic (IUPAC) name | |
[2-[(8R,10S,13S,14R,17R)- 17-hydroxy-10,13-dimethyl-3-oxo- 2,6,7,8,12,14,15,16-octahydro- 1H-cyclopenta[a]phenanthren-17-yl]- 2-oxo-ethyl] acetate |
|
Identifiers | |
CAS number | |
ATC code | S01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C23H30O5 |
Mol. mass | 386.48 |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status |
Schedule 4 (Aust) |
Routes | intravitreal depot injection |
Anecortave (rINN) (pronounced /ænəˈkɔrteɪv/) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus, it possesses little glucocorticoid activity. It will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.